GlassScriptPhysician profile
Tariq Akbar
NPI 1386692143
$8,892.18
in general payments reported to CMS, 2019-2025
35 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $754 · 2021: $957 · 2022: $1,330 · 2023: $1,058 · 2024: $2,049 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Travel and Lodging: $421 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,451.81 |
| Travel and Lodging | $420.69 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,943.85 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Boston Scientific Corporation | $760.85 | 2024 | Resolution 360 Ultra Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $699.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $443.97 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $372.97 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $317.74 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.09 | 2019-2025 | Trulance, Xifaxan |
| Genzyme Corporation | $253.65 | 2022-2025 | |
| Pfizer INC. | $208.26 | 2019-2025 | |
| Lilly USA, LLC | $195.89 | 2023-2025 | Omvoh, Jardiance |
| Olympus America INC. | $183.67 | 2023-2025 | Endoclot Sis, Endoclot Phs, Visiglide |
| Medtronic, INC. | $158.37 | 2022-2025 | Interstim |
| Ironwood Pharmaceuticals, INC | $138.06 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $124.29 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $122.76 | 2019-2024 | Dificid, Zerbaxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $121.62 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $59.31 | 2019-2022 | |
| Celgene Corporation | $55.97 | 2022-2024 | Zeposia |
| Romark Laboratories, Lc | $55.32 | 2019-2020 | |
| Qol Medical, LLC | $48.26 | 2022-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $46.63 | 2025 | Zenpep, Vowst |
| Vivus LLC | $34.89 | 2020-2025 | Pancreaze |
| Amgen INC. | $32.74 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $31.43 | 2024 | Iqirvo |
| Novo Nordisk INC | $26.97 | 2025 | Wegovy |
| Recordati_rare_diseases_inc. | $24.91 | 2024 | Signifor Lar, Isturisa |
| Alfasigma USA, INC. | $22.15 | 2020 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Fresenius Kabi USA, LLC | $17.60 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $17.35 | 2024 | Resmetirom |
| Redhill Biopharma INC. | $16.51 | 2022 | |
| Sandoz INC. | $16.00 | 2025 | Hyrimoz |
| Allergan, INC. | $12.47 | 2020 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Braintree Laboratories, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.